Related Experiment Videos
Gabapentin for hot flashes in prostate cancer
Sean M Jeffery1, Jeffrey J Pepe, Lisa M Popovich
1School of Pharmacy, University of Connecticut, West Haven 06156-2770, USA. Sean.Jeffery@med.va.gov
The Annals of Pharmacotherapy
|March 16, 2002
Summary
Gabapentin effectively treated refractory hot flashes in a prostate cancer patient undergoing antiandrogen and GnRH analog therapy. This finding offers a new treatment option for managing difficult hot flashes in cancer patients.
Area of Science:
- Oncology
- Pharmacology
- Men's Health
Background:
- Prostate cancer treatment often involves antiandrogen and gonadotropin-releasing hormone (GnRH) analog therapy.
- These therapies can induce severe and refractory hot flashes, significantly impacting patient quality of life.
- Existing treatments for these hot flashes are often ineffective.
Observation:
- A 70-year-old male patient with advanced prostate cancer experienced disabling hot flashes due to combination therapy with bicalutamide and goserelin acetate.
- The patient did not respond to conventional treatments including clonidine, megestrol acetate, diethylstilbestrol, and venlafaxine.
- Gabapentin was administered at a dose of 600 mg once daily.
Findings:
- Gabapentin resulted in near-complete resolution of the patient's hot flashes.
- This case supports previous findings on gabapentin's efficacy in reducing hot flash severity and duration.
- The exact mechanism by which gabapentin alleviates these symptoms remains unknown.
Implications:
- Gabapentin presents a promising therapeutic option for managing refractory hot flashes in prostate cancer patients.
- Further controlled trials are warranted to compare gabapentin with other treatment modalities.
- Effective management of treatment-induced hot flashes is crucial for maintaining treatment adherence and improving patient outcomes.